Skip to main content
SpringerLink
Log in

Individualized treatment with multiple antihypertensive agents is often necessary when treating hypertension in obese patients

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Treatment with a number of antihypertensive agents is usually necessary to achieve blood pressure control in patients with obesity-related hypertension. Diuretics, renin-angiotensin system inhibitors and dihydropyridine calcium channel blockers are commonly used first, with subsequent additions of aldosterone antagonists and/or dual α- and β-blocking agents as necessary. Treatment should be based on an understanding of the underlying mechanisms of obesity-related hypertension, and individualized according to patient characteristics and co-morbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Singer GM, Setaro JF. Secondary hypertension: obesity and the metabolic syndrome. J Clin Hypertens (Greenwich). 2008;10(7):567–74.

    Article  CAS  Google Scholar 

  2. Biaggioni I. Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension. 2008;51(2):168–71.

    Article  CAS  PubMed  Google Scholar 

  3. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904–10.

    Article  PubMed  Google Scholar 

  4. Kidambi S, Kotchen TA. Treatment of hypertension in obese patients. Am J Cardiovasc Drugs. 2013;13(3):163–75.

    Article  CAS  PubMed  Google Scholar 

  5. Trovato GM, Pace P, Martines GF, et al. Stress, abdominal obesity and intrarenal resistive index in essential hypertension. Clin Ter. 2012;163(4):299–305.

    CAS  PubMed  Google Scholar 

  6. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med. 1981;141(1):81–5.

    Article  CAS  PubMed  Google Scholar 

  7. Stelfox HT, Ahmed SB, Ribeiro RA, et al. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med. 2006;34(4):1243–6.

    Article  PubMed  Google Scholar 

  8. Strazzullo P, Barba G, Cappuccio FP, et al. Altered renal sodium handling in men with abdominal adiposity: a link to hypertension. J Hypertens. 2001;19(12):2157–64.

    Article  CAS  PubMed  Google Scholar 

  9. Lambert GW, Straznicky NE, Lambert EA, et al. Sympathetic nervous activation in obesity and the metabolic syndrome: causes, consequences and therapeutic implications. Pharmacol Ther. 2010;126(2):159–72.

    Article  CAS  PubMed  Google Scholar 

  10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.

    Article  CAS  PubMed  Google Scholar 

  11. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.

    PubMed  Google Scholar 

  12. Cooper-DeHoff RM, Gong Y, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001;134(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  14. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30(6):1047–55.

    Article  CAS  PubMed  Google Scholar 

  15. Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med. 2008;168(6):571–80.

    Article  CAS  PubMed  Google Scholar 

  16. Blumenthal JA, Sherwood A, Gullette EC, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med. 2000;160(13):1947–58.

    Article  CAS  PubMed  Google Scholar 

  17. Carroll JF, Kyser CK. Exercise training in obesity lowers blood pressure independent of weight change. Med Sci Sports Exerc. 2002;34(4):596–601.

    Article  PubMed  Google Scholar 

  18. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998;279(11):839–46.

    Article  CAS  PubMed  Google Scholar 

  19. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.

    Article  CAS  PubMed  Google Scholar 

  20. Sarkhosh K, Birch DW, Shi X, et al. The impact of sleeve gastrectomy on hypertension: a systematic review. Obes Surg. 2012;22(5):832–7.

    Article  PubMed  Google Scholar 

  21. Sjostrom CD, Lystig T, Lindroos AK. Impact of weight change, secular trends and ageing on cardiovascular risk factors: 10-year experiences from the SOS study. Int J Obes (Lond). 2011;35(11):1413–20.

    Article  CAS  Google Scholar 

  22. Modan M, Almog S, Fuchs Z, et al. Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension. 1991;17(4):565–73.

    Article  CAS  PubMed  Google Scholar 

  23. Mann SJ. Drug therapy for resistant hypertension: simplifying the approach. J Clin Hypertens (Greenwich). 2011;13(2):120–30.

    Article  Google Scholar 

  24. Sharma AM, Pischon T, Engeli S, et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001;19(4):667–74.

    Article  CAS  PubMed  Google Scholar 

  25. Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012;344:e42.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Schmieder RE, Gatzka C, Schachinger H, et al. Obesity as a determinant for response to antihypertensive treatment. BMJ. 1993;307(6903):537–40.

    Article  CAS  PubMed  Google Scholar 

  27. Stas S, Whaley-Connell AT, Sowers JR. Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2008;10(2):94–6.

    Article  Google Scholar 

  28. George J, Struthers AD. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin Pharmacother. 2007;8(17):3053–9.

    Article  CAS  PubMed  Google Scholar 

  29. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117(20):2706–15.

    Article  PubMed  Google Scholar 

  30. Masuo K, Mikami H, Ogihara T, et al. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001;14(6 Pt 1):530–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from the American Journal of Cardiovascular Drugs 2013;13(3):163–75 [4]. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. Individualized treatment with multiple antihypertensive agents is often necessary when treating hypertension in obese patients. Drugs Ther Perspect 30, 21–25 (2014). https://doi.org/10.1007/s40267-013-0077-1

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-013-0077-1

    Keywords

    Search

    Navigation